Alle Studien
RekrutierungHumane Pharmakologie (Phase I) - SonstigesInterventionell

Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

This study is investigating a new medicine called NNC0487-0111. It's designed for adults who have both obesity and type 2 diabetes. The main goal is to understand how the body processes this medicine after a single injection under the skin. We're especially interested in how it works in people with different levels of kidney function, from normal kidneys to those with some kidney problems. We'll also be checking for any side effects and how well people tolerate the medicine. This is an early-stage study, meaning we're gathering important basic information about this potential new treatment.

Auf einen Blick

Status
Rekrutierung
Phase
Humane Pharmakologie (Phase I) - Sonstiges
Sponsor
Novo Nordisk A/S
Einschreibeziel
42
Starten
25. Juni 2024

Worum geht es in dieser Studie?

Imagine your body as a busy factory. When you take a medicine, your factory processes it, uses what it needs, and then gets rid of the rest. This study, called an early-stage trial, is like a detailed inspection of how your body's factory handles a specific new medicine, NNC0487-0111. This medicine is being developed for people who live with two common health conditions: obesity and type 2 diabetes.

The main aim is to understand a few key things. First, we want to see how quickly the medicine gets into your system, how long it stays there, and how your body breaks it down and removes it. This is important because it helps scientists figure out the best way to give the medicine in the future. Second, we're very carefully checking for any unwanted effects or side effects, and how well people feel while taking the medicine. Your safety and comfort are always the top priority.

What makes this study particularly important is that it focuses on people with different levels of kidney health. Kidneys play a big role in clearing medicines from the body. So, understanding how NNC0487-0111 works in people with normal kidney function compared to those with some kidney problems will help ensure that if this medicine becomes available, it can be used safely and effectively by a wide range of patients.

Wichtige Erkenntnisse

  • This is an early study of a new medicine for obesity and type 2 diabetes.
  • It aims to understand how the medicine works in the body and if it's safe.
  • It specifically looks at how the medicine is processed by people with different kidney health.
  • Participation involves a single injection and several follow-up visits.
  • You must be an adult with both obesity and type 2 diabetes to be eligible.

Wer könnte berechtigt sein?

To join this study, you need to be an adult, aged 18 or older. Both men and women are welcome to take part.

Because this study is looking at how the body handles the new medicine, they will be including people with normal kidney function as well as those who have different levels of kidney impairment.

The study is specifically for individuals who have been diagnosed with both obesity and type 2 diabetes.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a diagnosis of obesity?
  3. Do you have a diagnosis of type 2 diabetes?
  4. Are you able to attend several study appointments?
  5. Are you willing to receive a single injection under your skin?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you would receive a single injection of the study medicine under your skin. Your participation will involve several visits to the clinic where the research team will perform various assessments. These will likely include blood tests to measure the medicine levels in your body, check your kidney function, and ensure your overall health. They will also monitor you closely for any side effects and ask you about how you are feeling. The exact number of visits and the total length of time you'd be involved will be explained in detail before you agree to participate.

Potenzielle Risiken und Vorteile

Taking part in a study like this means you might get access to a new medicine that could potentially help your conditions, though there's no guarantee. However, there are also potential risks; you might experience side effects from the study medicine, or the medicine might not help you. All medical procedures carry some risks, such as discomfort from blood tests. You will be closely monitored by medical professionals, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Deutschland

Häufige Fragen

What is NNC0487-0111?

It's a new experimental medicine being tested for people with obesity and type 2 diabetes. It's not yet available outside of clinical trials.

What does 'single subcutaneous dose' mean?

It means you'd receive just one injection of the medicine, given under the skin, similar to how many diabetes medicines are given.

Why are they studying people with kidney problems?

Kidneys help remove medicines from the body. It's important to understand how this new medicine works in people with different kidney health to make sure it's safe for everyone.

Is this medicine available to the public?

No, this is an early-stage research study, so the medicine is not yet available for general prescription.

Will I know if I'm getting the actual medicine?

In some studies, participants know what they're receiving; in others, it's 'blinded'. The study team will explain this to you fully.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Investigation of pharmacokinetics, safety and tolerability o… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.